| HOME >> BIOLOGY >> TECHNOLOGY |
"This CE marking of the Tissue Genesis Cell Isolation System marks an important milestone for Bioheart as we transition into a commercial company," said Howard J. Leonhardt, Bioheart's Chairman, CEO and CTO. "We are extremely excited to commence shipping the systems to our customers."
In addition to the Bioheart license and distribution agreement, SpineSmith LP -- a developer of implants and biologics for surgical fixation, correction and tissue regeneration of the spine -- recently provided two Tissue Genesis Cell Isolation Systems, expected to be used in spinal fusion study.
"We expect the study of the use of Tissue Genesis Cell Isolation System fat derived stem cells to be a significant milestone for tissue regeneration. We look forward to helping surgeons harness the tremendous benefits of autologous adult stem cells from adipose for their spinal fusions," commented Kevin Dunworth, founder of SpineSmith.
Tissue Genesis also has a license and distribution agreement with Vet-Stem, Inc. "The CE mark is major milestone for the company. As the licensee for the world veterinary markets, the CE mark adds credibility and professionalism to a system that is already the leader in its class," Bob Harman, DVM, Vet-Stem CEO.
"Clearly, a demand for our technology exists," added Krucky. "We are committed to manufacturing and delivering systems of the highest quality to our current partners, as well as to potential licensees. The application of the CE mark on our Tissue Genesis Isolation System is a major step toward our commitment to European patients who will benefit from our technology -- We help you heal yourself(TM)."
About Tissue Genesis, Inc.
Tissue Genesis, Inc. (http://www.tissuegenesis.com) is a leader in adipose
(fat) derived regenerative medicine solutions to address a wide range of
therape
'/>"/>
| SOURCE Tissue Genesis, Inc. Copyright©2008 PR Newswire. All rights reserved |